“These positive progression-free survival results from the ECHO Phase III trial could provide a new standard of care for patients with mantle cell lymphoma,” says our Michael Wang, MD of combination therapy with acalabrutinib. brnw.ch/21wJs82 #lymphoma #EndCancer

Researchers at Penn have uncovered important biological mechanisms underlying T cell exhaustion in chronic diseases and cancer, published recently in Cell: cell.com/cell/abstract/… (1/3)

Penn Cell The work advances our understanding of T cell exhaustion and receptor biology, with insights on: LAG-3 orchestrating T cell response to cancer, how LAG-3 and PD-1 work differently to regulate immune responses & Qa-1b, a potential new cancer detection pathway. (2/3)

MALT1 is elevated in multiple myeloma, and its inhibition is beneficial (Yao et al, Xuzhou Med Univ, Blood Advances); we got similar results for #MCL (jci.org/articles/view/…). Inhibition was associated with immunogenic cell death. tinyurl.com/MMMALT1

Have a cool weekend!

Blood Review article shows MRD-tests to predict relapse at the individual level sensitivity are often <50% with substantial numbers of false-negative and-positives. This consideration undermines using results of MRD-testing to inform therapy-decisions. tinyurl.com/MDRper

Cancer therapy-induced polyploidy promotes acquired resistance and aggressive disease. Conway et al of UTHSC San Antonio show that induced polyploidy arising from endomitosis in DLBCL models was eliminated by Aurkin A, an AK-A/TPX2 inhibitor. tinyurl.com/ploidy

Have a great weekend, enjoy the outdoors!

In Molecular Therapy, Seoul National University’s Ahn et al. review properties of T-cell exhaustion and revitalization strategies to improve therapeutic impact. Approaches to improve long-term persistence of CAR-T and T cells are especially compelling. tinyurl.com/TiredT

Dr. Michael Wang weighs in on results from the Phase III ECHO trial for older mantle cell lymphoma patients who received a BTK inhibitor with chemoimmunotherapy: bit.ly/4e0msm1 Michael Wang, MD #Lymphoma #EndCancer

Studying cytokines and M2 macrophages in the ibrutinib resistance of #MCL, Sun et al (Sun Yat-sen Univ) found that macrophage-secreted CXCL5 interacted with MCL cell CXCR2; blocking CXCR2 with SB225002 and ibrutinib suppressed MCL growth. tinyurl.com/CXCR2-MCL

Have a relaxing long weekend!

Phenotype/lineage plasticity of cancer cells is associated with therapy resistance. In Trends in Cancer, Perez et al. of Cedars-Sinai review the relationships of metabolic reprogramming and epigenetics to such plasticity. tinyurl.com/5y7u4nxc

Wishing you a great weekend!

Yesterday, at the SOHO meeting in Houston, I discussed “the next questions in mantle cell lymphoma”. Many who were not there are curious what those questions were.

An extensive Cancer Research review from University of Alabama at Birmingham summarizes various aspects of ribosome biogenesis on cancer metastasis, therapeutic resistance, and clinical outcome. tinyurl.com/RiboReview

In Trends in Cancer, Montauti et al (UCSF and Fred Hutch) review the latest evidence for the role of CD4+ T cells in the success of cancer immunotherapy, both by providing T-cell help and by cytotoxicity against tumor cells and some TME cells. tinyurl.com/CD4-immunoTx

I’ll be speaking at the Park City Myeloma and Lymphoma Summit on September 28th. Please consider reserving your place today at tinyurl.com/DrWangPresents

Have a great weekend!

A Mayo Clinic team showed in Nat Commun that IL4 mAb improves antitumor efficacy and reduces CART cell exhaustion in an MCL xenograft model. The strategy should be clinically translatable as many IL4 targeting therapies are in clinical development. tinyurl.com/IL4strat